PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal
Abstract
Authors
R. Guerreiro A.T. Paquete L. Iadeluca C. Almond F. Albuquerque de Almeida M. Inês J. Costa M. Borges L. Silva Miguel